Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02TIK
|
|||
| Former ID |
DCL000837
|
|||
| Drug Name |
HP-184
|
|||
| Synonyms |
Nerispirdine; Nerispirdine hydrochloride; HP 184; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 2 | [1] | |
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H18FN3
|
|||
| Canonical SMILES |
CCCN(C1=C(C=NC=C1)F)N2C=C(C3=CC=CC=C32)C
|
|||
| InChI |
1S/C17H18FN3/c1-3-10-20(17-8-9-19-11-15(17)18)21-12-13(2)14-6-4-5-7-16(14)21/h4-9,11-12H,3,10H2,1-2H3
|
|||
| InChIKey |
BTDHTARYCBHHPJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 119229-65-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated potassium channel Kv11.1 (KCNH2) | Target Info | Blocker | [1] |
| Voltage-gated sodium channel alpha Nav1.9 (SCN11A) | Target Info | Blocker | [1] | |
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Voltage gated Potassium channels | |||
| Interaction between L1 and Ankyrins | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Hematopoietic Stem Cell Differentiation | ||||
| Potassium Channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.